Technology area: Medical Devices & Mechanical Engineering
11 pending office actions • 5 art units • 10 examiners • 0 of 11 (0%) have an AI response strategy ready • 17 patents granted in the last 365 days
Mallinckrodt Pharmaceuticals Ireland Limited has 12 pending office actions in the Medical Devices & Mechanical Engineering technology area. These are distributed among 11 distinct examiners and several art units. The 6 distinct art units indicate a moderate level of technical diversity for the 12 pending actions. Most of the 11 distinct examiners are handling a single case.
ZHANG, TINA is the busiest examiner with 2 pending office actions. This examiner is the only one among the group with more than one active case for the company. The 12 pending office actions are spread across 6 distinct art units, which suggests that the company's intellectual property in Medical Devices & Mechanical Engineering is somewhat specialized. Practitioners should expect to navigate several technical groups, each potentially having different examination cultures for these active actions. The many distinct examiners involved mean that the company must manage a variety of examination styles.
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 5 (45%) |
| §112 only | 1 (9%) |
| Double-patenting + other | 1 (9%) |
| Multi-statute (no §101) | 4 (36%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZHANG, TINA | 2 | 56.1% | +44.6% |
| TRINH, HONG-VAN N | 1 | 62.8% | +57.0% |
| MURPHY, VICTORIA | 1 | 62.0% | +46.3% |
| WEN, SHARON X | 1 | 56.8% | +32.6% |
| LOUIS, LATOYA M | 1 | 52.3% | +40.3% |
| SIPPEL, RACHEL T | 1 | 52.5% | +58.2% |
| DIXON, ANNETTE FREDRICKA | 1 | 74.3% | +26.0% |
| SCOTLAND, REBECCA LYNN | 1 | 0.0% | +0.0% |
| DAHER, KIRA B | 1 | 42.4% | +56.1% |
| TOTH, KAREN E | 1 | 46.4% | +25.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17917209 | USE OF INHALED NITRIC OXIDE (iNO) FOR TREATMENT OF INFECTION, INCLUDING INFECTION WITH SARS-CoV2 AND TREATMENT OF COVID-19 | SCOTLAND, REBECCA LYNN | 54d |
| 17420406 | USE OF INHALED NITRIC OXIDE (iNO) FOR IMPROVING ACTIVITY LEVELS IN PATIENTS WITH LUNG-RELATED CONDITIONS | DAHER, KIRA B | 68d |
| 18802041 | APPARATUS AND METHOD FOR MONITORING NITRIC OXIDE DELIVERY | MURPHY, VICTORIA | — |
| 18109506 | SYSTEMS AND METHODS FOR INTELLIGENT GAS SOURCE MANAGEMENT | SIPPEL, RACHEL T | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19169718 | PRE-FILLED MANUAL INJECTOR APPARATUS | TRINH, HONG-VAN N | 9d overdue |
| 18109510 | SYSTEMS AND METHODS FOR DELIVERY OF THERAPEUTIC GAS | ZHANG, TINA | 3d overdue |
| 18000188 | METHOD FOR PULSATILE DELIVERY OF A GASEOUS DRUG | DIXON, ANNETTE FREDRICKA | 28d |
| 18416231 | COMPOSITIONS FOR IMPROVING KIDNEY FUNCTION IN PATIENTS WITH HEPATORENAL SYNDROME | WEN, SHARON X | 30d |
| 17420406 | USE OF INHALED NITRIC OXIDE (iNO) FOR IMPROVING ACTIVITY LEVELS IN PATIENTS WITH LUNG-RELATED CONDITIONS | DAHER, KIRA B | 68d |
| 18802041 | APPARATUS AND METHOD FOR MONITORING NITRIC OXIDE DELIVERY | MURPHY, VICTORIA | — |
| 18136522 | Methods Of Administering High Concentrations Of Nitric Oxide | LOUIS, LATOYA M | — |
| 18109506 | SYSTEMS AND METHODS FOR INTELLIGENT GAS SOURCE MANAGEMENT | SIPPEL, RACHEL T | — |
| Art Unit | Apps |
|---|---|
| 3785 | 7 |
| 3783 | 1 |
| 1641 | 1 |
| 1615 | 1 |
| 3791 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19169718 | PRE-FILLED MANUAL INJECTOR APPARATUS | TRINH, HONG-VAN N | 3783 | §103 | Final Rejection | 9d overdue | Pending | Apr 03, 2025 |
| 18802041 | APPARATUS AND METHOD FOR MONITORING NITRIC OXIDE DELIVERY | MURPHY, VICTORIA | 3785 | §103§112Other | Non-Final OA | — | Pending | Aug 13, 2024 |
| 18416231 | COMPOSITIONS FOR IMPROVING KIDNEY FUNCTION IN PATIENTS WITH HEPATORENAL SYNDROME | WEN, SHARON X | 1641 | §102§103DP | Final Rejection | 30d | Pending | Jan 18, 2024 |
| 18136522 | Methods Of Administering High Concentrations Of Nitric Oxide | LOUIS, LATOYA M | 3785 | §103 | Non-Final OA | — | Pending | Apr 19, 2023 |
| 18109506 | SYSTEMS AND METHODS FOR INTELLIGENT GAS SOURCE MANAGEMENT | SIPPEL, RACHEL T | 3785 | §102§103§112 | Non-Final OA | — | Pending | Feb 14, 2023 |
| 18109510 | SYSTEMS AND METHODS FOR DELIVERY OF THERAPEUTIC GAS | ZHANG, TINA | 3785 | §103 | Final Rejection | 3d overdue | Pending | Feb 14, 2023 |
| 18000188 | METHOD FOR PULSATILE DELIVERY OF A GASEOUS DRUG | DIXON, ANNETTE FREDRICKA | 3785 | §103 | Non-Final OA | 28d | Pending | Nov 29, 2022 |
| 17917209 | USE OF INHALED NITRIC OXIDE (iNO) FOR TREATMENT OF INFECTION, INCLUDING INFECTION WITH SARS-CoV2 AND TREATMENT OF COVID-19 | SCOTLAND, REBECCA LYNN | 1615 | §103§112Other | Non-Final OA | 54d | Pending | Oct 05, 2022 |
| 17420406 | USE OF INHALED NITRIC OXIDE (iNO) FOR IMPROVING ACTIVITY LEVELS IN PATIENTS WITH LUNG-RELATED CONDITIONS | DAHER, KIRA B | 3785 | §103§112 | Final Rejection | 68d | Pending | Jul 02, 2021 |
| 17055365 | METHOD AND APPARATUS FOR PULSATILE DELIVERY OF NITRIC OXIDE | ZHANG, TINA | 3785 | §103 | Final Rejection | — | Pending | Nov 13, 2020 |
| 16365263 | DEVICES AND METHODS FOR MONITORING OXYGENATION URING TREATMENT WITH DELIVERY OF NITRIC OXIDE | TOTH, KAREN E | 3791 | §112 | Non-Final OA | — | Pending | Mar 26, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMallinckrodt Pharmaceuticals Ireland Limited has 11 pending office actions as of October 2026, spread across 5 art units and 10 examiners.
Tina Zhang has the most, with 2 of Mallinckrodt Pharmaceuticals Ireland Limited's pending office actions.
Mostly Medical Devices & Mechanical Engineering (USPTO Tech Center 3700), based on where its pending office actions are examined.
